UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):      October 27, 2004
                                                      --------------------------


                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)


       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.1. below):

[ ]  Written  communications  pursuant  to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting   material  pursuant  to  Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement   communications   pursuant  to  Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications   pursuant  to  Rule  13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item 8.  Other Events.

Provectus  Pharmaceuticals,  Inc. (OTCBB:  PVCT) (UIR:FRK2541)  announced today,
October  27,  2004,   that  one  of  the  largest   national   distributors   of
pharmaceutical  products  has  accepted  delivery  of  the  company's  Pure-ific
antibacterial  hand  spray for sale in 504 stores in the  western  region of the
United States.

"We are particularly  happy to get this campaign started right now, at the onset
of cold and flu season,  and we expect to build upon this  beginning  and extend
sales into other regions of the country,"  said  Pure-fic  President  Timothy C.
Scott,  Ph. D. "This  first  shipment  of product is  destined  for sales in the
states of California, Utah, Arizona, and Washington."

Pure-ific, which comes in a 1-ounce can, immediately kills up to 99.9 percent of
germs  on  skin  and  prevents  re-growth  for up to six  hours.  Packaged  as a
quick-drying spray, Pure-ific is useful for mothers,  travelers, and anyone else
concerned  about  the  spread  of  germs.   Unlike  gel  sanitizers,   Pure-ific
Antibacterial  Hand Spray leaves no sticky residue and is  appropriate  both for
hands and for hard surfaces, such as toilet seats.

Provectus  Pharmaceuticals  Inc.  plans to license  and sell  products  in three
sectors of the health-care industry: 1) prescription medications and treatments,
2) medical  devices,  and 3)  over-the-counter  (OTC)  pharmaceuticals,  such as
Pure-ific.  Prescription  drug  products and devices  address  several  forms of
difficult-to-treat cancers as well as diseases of the skin. OTC products address
complementary markets, primarily those involving skin care and comfort.

The  company's  offices and  laboratory  are located at 7327 Oak Ridge  Highway,
Suite A Knoxville,  TN 37931;  telephone:  865/769-4011.  For more  information,
contact  the  company  at   info@pvct.com  or  visit  the  corporate  Web  site:
www.pvct.com.

Forward-Looking Statements

This information and others  statements  issued or made from time to time by the
company  or  its   representatives   contain   statements  that  may  constitute
forward-looking  statements.  Those statements include statements  regarding the
intent,  belief or  current  expectations  of the  company  and  members  of its
management  teams as well as the  assumptions on which the statements are based.
Prospective investors are cautioned that such forward-looking statements are not
guarantees of future  performance and involve risks and  uncertainties,and  that
actual  results  may  differ   materially   from  those   contemplated  by  such
forward-looking  statements.
___________________________

Corporate  Contact:  Provectus  Pharmaceuticals,  Craig Dees, CEO (865) 769-4011
Media Contacts:  Emily Carlton or George Pappas,  HKA, Inc., 714 426-0444 (PDT),
Emily@hkamarcom.com

Source: Provectus Pharmaceuticals Inc.

<PAGE>



                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      Provectus Pharmaceuticals, Inc.


Dated:   October 27, 2004             By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "pvct8k102004.txt", "description": "PUBLIC ANNOUNCEMENT", "secsgml_size_bytes": 5676}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "041098760"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):      October 27, 2004
                                                      --------------------------

                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)

       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.1. below):

[ ]  Written  communications  pursuant  to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting   material  pursuant  to  Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement   communications   pursuant  to  Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications   pursuant  to  Rule  13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))
Item 8.  Other Events.

Provectus  Pharmaceuticals,  Inc. (OTCBB:  PVCT) (UIR:FRK2541)  announced today,
October  27,  2004,   that  one  of  the  largest   national   distributors   of
pharmaceutical  products  has  accepted  delivery  of  the  company's  Pure-ific
antibacterial  hand  spray for sale in 504 stores in the  western  region of the
United States.

"We are particularly  happy to get this campaign started right now, at the onset
of cold and flu season,  and we expect to build upon this  beginning  and extend
sales into other regions of the country,"  said  Pure-fic  President  Timothy C.
Scott,  Ph. D. "This  first  shipment  of product is  destined  for sales in the
states of California, Utah, Arizona, and Washington."

Pure-ific, which comes in a 1-ounce can, immediately kills up to 99.9 percent of
germs  on  skin  and  prevents  re-growth  for up to six  hours.  Packaged  as a
quick-drying spray, Pure-ific is useful for mothers,  travelers, and anyone else
concerned  about  the  spread  of  germs.   Unlike  gel  sanitizers,   Pure-ific
Antibacterial  Hand Spray leaves no sticky residue and is  appropriate  both for
hands and for hard surfaces, such as toilet seats.

Provectus  Pharmaceuticals  Inc.  plans to license  and sell  products  in three
sectors of the health-care industry: 1) prescription medications and treatments,
2) medical  devices,  and 3)  over-the-counter  (OTC)  pharmaceuticals,  such as
Pure-ific.  Prescription  drug  products and devices  address  several  forms of
difficult-to-treat cancers as well as diseases of the skin. OTC products address
complementary markets, primarily those involving skin care and comfort.

The  company's  offices and  laboratory  are located at 7327 Oak Ridge  Highway,
Suite A Knoxville,  TN 37931;  telephone:  865/769-4011.  For more  information,
contact  the  company  at   info@pvct.com  or  visit  the  corporate  Web  site:
www.pvct.com.

Forward-Looking Statements

This information and others  statements  issued or made from time to time by the
company  or  its   representatives   contain   statements  that  may  constitute
forward-looking  statements.  Those statements include statements  regarding the
intent,  belief or  current  expectations  of the  company  and  members  of its
management  teams as well as the  assumptions on which the statements are based.
Prospective investors are cautioned that such forward-looking statements are not
guarantees of future  performance and involve risks and  uncertainties,and  that
actual  results  may  differ   materially   from  those   contemplated  by  such
forward-looking  statements.
___________________________

Corporate  Contact:  Provectus  Pharmaceuticals,  Craig Dees, CEO (865) 769-4011
Media Contacts:  Emily Carlton or George Pappas,  HKA, Inc., 714 426-0444 (PDT),
Emily@hkamarcom.com

Source: Provectus Pharmaceuticals Inc.
Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      Provectus Pharmaceuticals, Inc.

Dated:   October 27, 2004             By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer